Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns

Angelo D'Amico/iStock via Getty Images Pfizer (NYSE:PFE) has had a rough few quarters. Following a massive boom in revenue and profits that was the direct result of the company's prominent Covid products - including the vaccine (Comirnaty) and Paxlovid - shares have plunged as the pandemic has broadly receded as a global threat: TradingView However, as Covid-based revenue and profit has moved from a big chunk of PFE's revenue to a comparably smaller piece of the pie, PFE's stock, at this point, has once ...